SUJATHA KANNAN
Medical Practice in Detroit, MI

License number
Michigan 4301072890
Issued Date
Jul 2, 2003
Expiration Date
Jan 31, 2013
Category
Medicine
Type
Medical Doctor
Address
Address
Detroit, MI 48201

Personal information

See more information about SUJATHA KANNAN at radaris.com
Name
Address
Phone
Sujatha Kannan, age 53
44410 Midway Dr, Novi, MI 48375

Organization information

See more information about SUJATHA KANNAN at bizstanding.com

Sujatha Kannan MD,MBBS,BS

3901 Beaubien St, Detroit, MI 48201

Industry:
Pediatrician
Site:
Phone:
(313) 745-5629 (Phone)
Description:
There are 10 doctors at this site. Surgery is not performed at this site.
Sujatha Govind Kannan

Professional information

See more information about SUJATHA KANNAN at trustoria.com
Sujatha Kannan Photo 1
Dr. Sujatha Kannan, Detroit MI - MD (Doctor of Medicine)

Dr. Sujatha Kannan, Detroit MI - MD (Doctor of Medicine)

Specialties:
Pediatric Critical Care Medicine
Address:
Children's Hospital Of MI-PCT
3901 Beaubien St SUITE 4134, Detroit 48201
(313) 745-5629 (Phone)
Certifications:
Pediatric Critical Care Medicine, 2004, Pediatrics, 2000
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Jawaharlal Institute of Post-Graduate Medical Education / Madras University
University Il College Of Med
University Of Sd School Of Med
Wayne St University Detroit M C
Chldns Hospital Of Mi Wsu
Graduated: 2003


Sujatha Kannan Photo 2
Dendrimer Based Nanodevices For Therapeutic And Imaging Purposes

Dendrimer Based Nanodevices For Therapeutic And Imaging Purposes

US Patent:
2012000, Jan 5, 2012
Filed:
Jun 10, 2010
Appl. No.:
12/797657
Inventors:
Rangaramanujam M. Kannan - Detroit MI, US
Sujatha Kannan - Detroit MI, US
Roberto Romero - Gross Points MI, US
Raghavendra S. Navath - Somerset NJ, US
Hui Dai - Rochester Hills MI, US
Anupa R. Menjoge - Hayward CA, US
Assignee:
NATIONAL INSTITUTES OF HEALTH - Rockville MD
WAYNE STATE UNIVERSITY - Detroit MI
International Classification:
A61K 47/48, A61K 49/00, A61P 29/00, C08G 69/48
US Classification:
424 91, 525432, 525420, 424 7817
Abstract:
A nanodevice composition including N-acetyl cysteine linked to a dendrimer, such as a PAMAM dendrimer or a multiarm PEG polymer, is provided. Also provided is a nanodevice for targeted delivery of a compound to a location in need of treatment. The nanodevice includes a PAMAM dendrimer or multiarm PEG polymer, linked to the compound via a disulfide bond. There is provided a nanodevice composition for localizing and delivering therapeutically active agents, the nanodevice includes a PAMAM dendrimer or multiarm PEG polymer and at least one therapeutically active agent attached to the PAMAM dendrimer or multiarm PEG polymer. A method of site-specific delivery of a therapeutically active agent, by attaching a therapeutically active agent to a PAMAM dendrimer or multiarm PEG polymer using a disulfide bond, administering the PAMAM dendrimer or multiarm PEG polymer to a patient in need of treatment, localizing the dendrimer or multiarm PEG polymer to a site in need of treatment, and releasing the therapeutically active agent at the site in need of treatment.


Sujatha Kannan Photo 3
Injectable Dendrimer Hydrogel Nanoparticles

Injectable Dendrimer Hydrogel Nanoparticles

US Patent:
2013013, May 30, 2013
Filed:
Mar 31, 2011
Appl. No.:
13/636715
Inventors:
Rangaramanujam M. Kannan - Detroit MI, US
Sujatha Kannan - Detroit MI, US
Roberto Romero - Grosse Point MI, US
Raghavendra Navath - Somerset NJ, US
Anupa Menjoge - New Hyde Park NY, US
Assignee:
NATIONAL INSTITUTES OF HEALTH - Rockville MD
WAYNE STATE UNIVERSITY - Detroit MI
International Classification:
A61K 47/48
US Classification:
424 96, 514420, 424400, 514197
Abstract:
The invention discloses injectable hydrogels which are in the form of crosslinked nano beads or particle in the size range 5 nm to 10 μm, comprising PAMAM dendrimer with asymmetrical peripheral end groups such that one of the terminal groups is involved in formation of hydrogel and the other in involved in the conjugation of drugs or imaging agents and their methods of preparation. The said gel is formed by reaction of the PAMAM dendrimer with asymmetrical end groups with other polymer wherein the other polymer is selected from the group of linear, branched, hyperbranched or star shaped polymers with functionalized terminal groups. The PAMAM dendrimer with asymmetrical terminal groups consists of a Generation 2 and above PAMAM dendrimer with symmetrical end groups modified using the amino acids or their modified forms. The gel disclosed in the present invention is formed as small crosslinked particles in the size range 25 nm to 10 μm and is suitable for injectable delivery of hydrogel to any of the body orifices, tissues by intramuscular or subcutaneous route and ocular delivery for the purpose of therapeutic treatment and imaging.